^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JCAR018
i
Other names: JCAR018, anti-CD22 chimeric antigen receptor T-cells, T-cell chimeric antigen receptor cellular therapy targeting CD-22, CD22-CAR, JCAR-018, JCAR 018, anti-CD22-human scFv CAR T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS, National Cancer Institute
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
2ms
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=133, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2040 --> Oct 2024
Trial completion • Trial completion date
|
CD22 (CD22 Molecule)
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
11ms
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=123, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
Enrollment closed
|
CD22 (CD22 Molecule)
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
1year
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=123, Suspended, National Cancer Institute (NCI) | N=208 --> 123 | Recruiting --> Suspended
Enrollment change • Trial suspension
|
CD22 (CD22 Molecule)
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
over2years
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (clinicaltrials.gov)
P1, N=23, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Enrollment open
|
CD22 (CD22 Molecule)
|
cyclophosphamide • JCAR018
over3years
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=208, Recruiting, National Cancer Institute (NCI) | N=126 --> 208
Clinical • Enrollment change
|
CD22 (CD22 Molecule)
|
JCAR018
over3years
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (clinicaltrials.gov)
P1, N=23, Not yet recruiting, National Cancer Institute (NCI)
Clinical • New P1 trial • IO biomarker
|
CD22 (CD22 Molecule)
|
JCAR018
Share via
